A Phase 4 interventional study of betamethasone valerate 0.1% cream and Placebo cream in Urinary Tract Infection, sponsored by Baylor College of Medicine. Recruiting at 3 sites in United States. Open to male participants aged 0 Months to 5 Months. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Baylor College of Medicine · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 275 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 57 under way, 2 of them phase 3. Urinary Tract Infections · United States.
Among the 275 studies in Urinary Tract Infections with a site in United States, this one is the 153rd largest by planned enrollment of the 225 interventional ones that give a count, is one of 19 that started in 2026, is one of 40 in phase 4, reaches primary completion later than 38 of the 56 other live ones, and was the 262nd registered.
808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.
Browse Urinary Tract Infections studies →44 of the 275 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15–50 · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
GlaxoSmithKline · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
Megan Bradley · Sites in United States
Ages 65+ · Women only
Ohio University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 0 Months to 5 Months · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
275 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 41 · Phase 3 33 · Phase 4 40
First in 1988; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 131 across 564 interventional studies indexed under Urinary Tract Infections.
Median enrollment 100 across the 225 interventional studies, 229 across the 50 observational. Of the 190 that completed or were terminated, 89 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 275 have an industry lead sponsor. The 10 most frequent:
Baylor College of Medicine is the lead sponsor of 747 studies on the registry; 110 are open to participants now.
Of its 84 completed or terminated interventional studies of FDA-regulated products, 45 (54%) have results posted.
Baylor College of Medicine has 7 studies filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
26 of the studies in Urinary Tract Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07686055Phase 3Megan BradleyPrecision Management of Urinary Tract Symptoms in Older Women | 2027-02-01 |
| NCT07947108Good Kitty CoA Clinical Trial to Evaluate the Effects of a Supplement on Urinary Symptoms | 2026-12 |
| NCT06976125University Hospitals Cleveland Medical CenterApplication of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting | 2026-12-01 |
| NCT07453693Bonafide HealthAn Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement | 2026-12-15 |
| NCT07542834Ohio UniversityUsing Virtual Reality to Improve Medical Training | 2026-12-31 |
Add all 26 to your calendar (.ics) → With an account.
Among the 275 studies in Urinary Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this smaller clinical trial is to evaluate the study design of this research to help prepare for a larger research study in the future. The future larger study would focus on whether steroid cream can reduce recurrent urinary tract infections in male infants, who are not circumcised.
Male infants, who are enrolled in this study, would receive either the steroid cream or a placebo cream (a look alike cream without steroids). The cream would be applied twice a week for four weeks. Then there would be two follow up visits with the research team to measure whether the infant experienced any urinary tract infections and to measure parent perceptions of their experience participating in the study.
This is a multi-center pilot study involving recruitment of uncircumcised male infants \< 6 months of age from outpatient clinics, emergency department and inpatient settings in Houston, Texas. Additionally, the pilot study will involve recruitment of hospitalized infants from Seattle Children's Hospital in Seattle, Washington.
Various strategies for screening and recruitment will be piloted across settings to identify the most effective processes for the future study. Hospitalized infants would be enrolled prior to discharge. Children recruited from the clinic or emergency department would be enrolled in the Texas Children's Hospital Clinical Research Center. Randomization would occur after enrollment and would be conducted by the investigational pharmacy. The research investigators will teach the legal guardians of the infants how to apply the cream.
The first follow up visit would occur after completion of the cream treatment and would be 28-38 days after being enrolled or after hospital discharge, whichever came later. The last follow up visit would occur 6-7 months after being enrolled or hospital discharge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: betamethasone valerate 0.1% cream
Drug: Placebo cream
Steroid cream applied to the foreskin and glans twice a day for four weeks.
Placebo cream is applied to the foreskin and glans twice a day for four weeks.
Feasibility of recruitment across different settings
Defined as the consent rate of \>= 20% as stratified by setting (clinic/EC/inpatient)
Time frame: up to 2 weeks
Rate of recurrent urinary tract infection
Defined as at least one subsequent urinary tract infection as confirmed through parent report and medical record review.
Time frame: Between 14 days of completing antibiotics for the first urinary tract infection and through the last follow up visit, which occurs 6 months after randomization.
Total number of recurrent urinary tract infections
Time frame: 6 month follow up period
Number of subsequent hospitalizations for recurrent urinary tract infections
Subsequent hospitalizations for recurrent urinary tract infections
Time frame: 6 month follow up period
Number of subsequent emergency department visits for recurrent urinary tract infection
Subsequent emergency department visits, including urgent care, for recurrent UTI
Time frame: Within 6 month follow up period
Rate of provider diagnosed recurrent urinary tract infection
Number of recurrent urinary tract infections that are diagnosed by the physician but do not necessarily meet laboratory criteria for urinary tract infection.
Time frame: 6 month follow up period
Number of Lumbar punctures
Number of lumbar punctures received during a subsequent emergency department visit or hospitalization for recurrent urinary tract infection
Time frame: 6 month follow up period
Self reported Rate of Referral for Circumcision
Parent reports referral to Urology for circumcision or circumcision performed within the 6 month follow up period.
Time frame: During the 6 month follow up period
Self Reported Adherence to Applying Topical Cream Regimen
Adherence to applying the topical cream measured by asking the frequency of application in a questionnaire completed by the legal guardian.
Time frame: Measured at 4 week follow up visit
Rate of Adverse effects of cream
Local or systemic side effects of the cream (e.g., irritation, local infection)
Time frame: At 4 weeks
Number of infants with Congenital anomalies of the kidney and urinary tract
Number of participants with previously known or newly diagnosed genitourinary anomalies
Time frame: From time of enrollment through last follow up visits 6 months later
Number of subsequent clinic visits for recurrent urinary tract infection
Subsequent clinic visits may include visits to the primary care physician or another physician in the clinic
Time frame: During the 6 month follow up period
Attrition rate
Total number of missed visits at 4 weeks and 6 months. This will be measured by tracking of study visits.
Time frame: Through the 6 month follow up period for each participant
Parental acceptability of the study design
Perceptions on any facilitators and barriers to participating in the study as related to enrollment, administration of the study cream and attending follow up visits. Qualitatively measured using semi-structured interviews.
Time frame: At the 6 month follow up visit for each participant
Plan to share: Yes — After publication of this study, a releasable database will be produced and completely de-identified in accordance with the definitions provided in the Health insurance Portability and Accountability Act (HIPAA). Namely, all identifiers specified in HIPAA will be recoded in a manner that will make it impossible to deduce or impute the specific identity of any patient. The database will not contain any institutional identifiers. The PI will prepare a data dictionary that provides a concise definition of every data element included in the database. The releasable database will be provided to users in electronic form.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: The de-identified database and data dictionary will be available after publication of this study and up to five years after the publication date.
Access criteria: The database and data dictionary would be made available to researchers and clinicians after publication of this study. The data will be made available upon publication to researchers who provide a methodologically sound proposal for use in achieving the goals of the approved proposal. Proposals should be submitted to Sowdhamini Wallace (swallace@bcm.edu).
Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.
Of 45 non-industry phase 4 interventional studies under Urinary Tract Infections, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 54. This study's planned 19 months is below that.
Counting every sponsor, half of 51 studies reached it within 37 months; a quarter within 22 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Betamethasone Valerate